Cambridge Nutritional Sciences PLC Warrant Expiry and Block Admission Cancellation (0080T)

TIDMCNSL

RNS Number : 0080T

Cambridge Nutritional Sciences PLC

10 November 2023

Cambridge Nutritional Sciences plc

(the 'Company' or 'CNS')

Warrant Expiry

and

Block Admission Cancellation

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that all warrants issued alongside its capital raise announced 6 May 2022 have now expired ("Warrants").

Further to the above the Company has made application to AIM to cancel the Company's Block Admission, which was originally established to facilitate the issuance of ordinary shares following receipt of any exercise of the Warrants (the "Cancellation"). The Cancellation will become effective Monday 13 November, as such no further interim returns will be published in relation to the Company's Block Admission. The Balance of ordinary shares under the Block Admission not issued/allotted at the time of Cancellation is 90,000,000.

Contacts:

 
 Cambridge Nutritional Sciences plc                                            www.cnsplc.com 
 Jag Grewal, Chief Executive Officer                                          via Walbrook PR 
 
 
 Cavendish Capital Markets Limited                                         Tel: 020 7220 0500 
 Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance) 
 Nigel Birks / Harriet Ward (ECM) 
 
 
 Walbrook PR Limited                                 Tel: 020 7933 8780 or CNS@walbrookpr.com 
 Paul McManus / Charlotte Edgar                            Mob: 07980 541 893 / 07884 664 686 
 Sam Allen                                                                 Mob: 07502 558 258

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKZMGMNLGGFZM

(END) Dow Jones Newswires

November 10, 2023 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Oct 2024 to Nov 2024